Paroxysmal atrial fibrillation after high-dose melphalan in five patients autotransplanted with blood progenitor cells

Bone Marrow Transplantation

Volumn 21, Issue 10, 1998, Pages 1049-1053

  Olivieri, A ^a   Corvatta, L ^a   Montanari, M ^a   Brunori, M ^a   Offidani, M ^a   Ferretti, G F ^a   Centanni, M ^a   Leoni, P ^a  

^a UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

High dose melphalan; Paroxysmal atrial fibrillation; Peripheral blood stem cell transplantation

Indexed keywords

MELPHALAN;

ADULT; ARTICLE; DOSE RESPONSE; FEMALE; HEART ATRIUM FIBRILLATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SINUS RHYTHM;

EID: 0031745558     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701217     Document Type: Article

References (26)

1. Selby PJ, McElwain TJ, Nandi AC. Multiple myeloma treated with high-dose intravenous melphalan. Br J Haematol 1987; 66: 55-61.
2. Alexanian E, Bergsagel DE, Migliore PJ et al. Melphalan therapy for plasma cell myeloma. Blood 1968; 31: 1-10.
3. Smith JP, Rutledge F. Advances in chemotherapy for gynecologic cancer. Cancer 1975; 36: 669-674.
4. Fisher B, Carbone P, Economou SG et al. L-phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. New Engl J Med 1975; 292: 117-122.
5. Souhami R, Peters W. High dose chemotherapy in solid tumors in adults. Clin Haematol 1986; 15: 219-234.
6. Barlogie B, Jagannath S, Dixon DO et al. High dose melphalan and granulocyte-macrophage colony stimulating factor for refractory multiple myeloma. Blood 1990; 76: 677-680.
7. Harrousseau JL, Milpied N, LaPorte JP et al. Double-intensive therapy in high risk multiple myeloma. Blood 1992; 79: 2827-2833.
8. Cunningham D, Paz-Ares L, Milan S et al. High dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma. J Clin Oncol 1994; 12: 759-763.
9. Vesole DH, Barlogie B, Jagannath S et al. High dose therapy for refractory multiple myeloma: improved prognosis with better supportive care and double transplants. Blood 1994; 84: 950-956.
10. Chopra R, McMillan AK, Linch DC et al. The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single center eight-year study of 155 patients. Blood 1993; 81: 1137-1145.
11. Barlogie B, Hall R, Zander A et al. High-dose melphalan with autologous bone marrow transplantation for multiple myeloma. Blood 1986; 67: 1298-1301.
12. Gore ME, Viner C, Meldrum M et al. Intensive treatment of multiple myeloma and criteria for complete remission. Lancet 1989; 2: 879-881.
13. Cunningham D, Paz-Ares L, Gore ME et al. High dose melphalan for multiple myeloma: long term follow-up data. J Clin Oncol 1994; 12: 764-768.
14. Jagannath S, Barlogie B, Dicke K et al. Autologous bone marrow transplantation in multiple myeloma: identification of prognostic factors. Blood 1990; 76: 1860-1866.
15. Fermand JP, Chevret S, Ravard P et al. High dose chemoradiotherapy and aulologous blood stem cell transplantation in multiple myeloma: results of phase II trial involving 63 patients. Blood 1993; 82: 2005-2009.
16. Samuels BL, Bitran JD. High-dose intravenous melphalan: a review. J Clin Oncol 1995; 13: 1786-1799.
17. Gottdiener JS, Appelbaum FR, Ferrans VJ et al. Cardiotoxicity associated with high-dose cyclophosphamide therapy. Arch Intern Med 1981; 141: 758-763.
18. Gianni AM, Bregni M, Siena S et al. Recombinant human granulocyte-macrophage colony-stimulating factor reduces hematological toxicity and widens clinical applicability of high-dose cyclophosphamide treatment in breast cancer and non-Hodgkin's lymphoma. J Clin Oncol 1990; 8: 768-778.
19. Velasquez WS, Cabanillas F, Salvador P et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethazone (DHAP). Blood 1987; 71: 117-122.
20. Gianni AM, Bregni M, Siena S et al. Granulocyte-macrophage colony stimulating factor or granulocyte-colony stimulating factor infusion makes high-dose etoposide a safe outpatient regimen that is effective in lymphoma and in myeloma patients. J Clin Oncol 1992; 10: 1955-1962.
21. Sahan DJ, de Maria A, Kisslo J, Weyman A. Recommendations regarding quantitation in M-Mode echocardiographic measurements. Circulation 1977; 58: 613-618.
22. Teihholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: echocardiographic-angiographic correlations in the presence or absence of assynergy. Am J Cardiol 1976; 37: 7-12.
23. Lopez-Jimenez J, Cervero C, Munoz A et al. Cardiovascular toxicities related to the infusion of cryopreserved graft: results of a controlled study. Bone Marrow Transplant 1994; 13: 789-793.
24. Physicians' Desk Reference. Medical Economics Company: Montvale, 1995.
25. Ardiet C, Tranchand B, Biron P et al. Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis. Cancer Chemother Pharmacol 1986; 16: 300-305.
26. 2 melphalan followed by autologous stem cell transplantation in patients with advanced haematological malignancies: pharmacokinetics and toxicity. Br J Haematol 1996; 95: 527-530.